We are developing innovative, cost-effective manufacturing processes for niche fermentation-based Active Pharmaceutical Ingredients that have clinical relevance in the field of immunology, oncology, and rare diseases. Our expected timeline for commercialization is the second quarter of 2027.
Tacrolimus is a biosynthetic macrolide with immunosuppressive properties. It is a calcineurin inhibitor that inhibits the Nuclear factor NFAT, thereby decreasing the synthesis of inflammatory cytokines.
Tacrolimus is used as primary therapy for renal and hepatic transplantation with 10-100 times higher efficacy than Cyclosprine.
Therapeutic Relevance
Sirolimus, also known as Rapamycin, is a biosynthetic small molecule with immunosuppressive, anti-fungal, and anti-proliferative properties. It is an mTOR inhibitor that blocks a protein complex called mTOR (mammalian target of Rapamycin), resulting in the prevention of cell-cycle progression from G1 to S phase downstream.
Therapeutic Relevance
Daptomycin is a biosynthetic cyclic lipopeptide antibiotic with potent bactericidal activity against Gram-positive pathogens. It binds to the bacterial cell membrane, causing rapid membrane depolarization. This disruption results in inhibition of DNA, RNA, and protein synthesis, ultimately leading to bacterial cell death. Daptomycin is active against multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Therapeutic Relevance